Plandai Biotechnology, Inc. (OTC:PLPL) has been relentlessly pumped since Jan. 23 and after a short nine-day brake there are more tout emails coming in.
Yesterday PLPL closed up 27.23% at $0.2799 on approximately 190.5 thousand shares, although there were no filings or news.
Promotions, on the other hand started piling up again. About four newsletters sent out emails about PLPL. Compensations range from $5 thousand to $25 thousand.[BANNER]
The latest announcement is from March 19 when the company launched a new “investor friendly website.” PLPL has aided the hype from promotions through a number of press releases.
Other than the paid pumps and press releases, filled with optimistic plans, PLPL may not have much to offer. The latest available financial report showed PLPL had limited assets and was operating at a loss.
On Jan. 25 PLPL issued a press release about $13 million in debt financing through Dunn Roman Holdings Africa (Proprietary) Ltd, a South African subsidiary.
CEO, Roger Duffield said the financing was non-dilutive, but the press release failed to provide details for the terms, and PLPL hasn’t filed any document to provide more information.
It’s very early to say for sure what will happen with PLPL in the long run; what seems obvious at this point is that the company still has the attention of promoters and traders who enjoy trading on the hype.
